SGLT2 Inhibitor Use Tied to Fewer Atrial Arrhythmias SGLT2 Inhibitor Use Tied to Fewer Atrial Arrhythmias
Patients with cardiac implantable electronic devices who were treated with an SGLT2 inhibitor had significantly fewer atrial arrhythmias vs those never receiving them, new observational data suggest.Medscape Medical News (Source: Medscape FamilyMedicine Headlines)
Source: Medscape FamilyMedicine Headlines - December 2, 2021 Category: Primary Care Tags: Cardiology News Source Type: news

Algorithm Predicts Response to SGLT2, DPP-4 Inhibitors in Diabetes Algorithm Predicts Response to SGLT2, DPP-4 Inhibitors in Diabetes
British investigators derived and validated an algorithm, available online, for predicting response of patients with type 2 diabetes to agents from two different classes of glucose-lowering drugs.First Look (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - November 29, 2021 Category: Internal Medicine Tags: Diabetes & Endocrinology News Source Type: news

At What Price Will Newer Anti-Diabetes Drugs Be Cost Effective? At What Price Will Newer Anti-Diabetes Drugs Be Cost Effective?
In low- to middle-income countries, SGLT2 inhibitors could reduce diabetes complications at lower but feasible prices; they are cost effective at current prices in people with heart or kidney disease.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 24, 2021 Category: Cardiology Tags: Diabetes & Endocrinology News Source Type: news

Canagliflozin Improves HF Symptoms in Fully Remote Trial Canagliflozin Improves HF Symptoms in Fully Remote Trial
The benefit of the SGLT2 inhibitor was consistent, regardless of ejection fraction and presence or absence of type 2 diabetes, in the decentralized CHIEF-HF trial.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 17, 2021 Category: Cardiology Tags: Cardiology News Source Type: news

Empagliflozin Wins in Tough Stabilized Acute-HF Setting Empagliflozin Wins in Tough Stabilized Acute-HF Setting
Early in-hospital initiation of SGLT2 inhibitors ' should be considered the new standard of care ' in most patients with heart failure regardless of their ejection fraction, says an expert observer.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 16, 2021 Category: Cardiology Tags: Cardiology News Source Type: news

Which Patients With Type 2 Diabetes Need SGLT2 Inhibitors? Which Patients With Type 2 Diabetes Need SGLT2 Inhibitors?
With an essential role established for SGLT2 inhibitors for patients with progressive renal dysfunction or heart failure, researchers discuss how best to use these agents in those with type 2 diabetes.Medscape Medical News (Source: Medscape FamilyMedicine Headlines)
Source: Medscape FamilyMedicine Headlines - October 28, 2021 Category: Primary Care Tags: Diabetes & Endocrinology News Source Type: news

Which Patients With Type 2 Diabetes Need SGLT2
Inhibitors? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - October 28, 2021 Category: General Medicine Source Type: news

SGLT2 Inhibitors for Diabetes: No Link to Fractures in Older Adults SGLT2 Inhibitors for Diabetes: No Link to Fractures in Older Adults
Analysis of Medicare data supports findings from younger adults that use of the drug class does not appear to raise fracture risk.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - October 27, 2021 Category: Cardiology Tags: Diabetes & Endocrinology News Source Type: news

Optimal Use of SGLT2 Inhibitors and GLP-1 Agonists Optimal Use of SGLT2 Inhibitors and GLP-1 Agonists
In light of the vast benefits demonstrated by SGLT2 inhibitors and GLP-1 agonists, Dr Matthew Budoff highlights how cardiologists and preventive care physicians can optimize their use in patient care.American College of Cardiology & Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 18, 2021 Category: Consumer Health News Tags: Cardiology Article Source Type: news

Differential Mechanisms in HFrEF and HFpEF in Diabetes Differential Mechanisms in HFrEF and HFpEF in Diabetes
This review explores the pathophysiological mechanisms of heart failure in patients with diabetes, how they differ in patients with HFrEF vs. HFpEF, and the use of SGLT2 inhibitors in these patients.JACC: Heart Failure (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 8, 2021 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

Which New Drug Class Is Best for Heart Protection in Type 2 Diabetes? Which New Drug Class Is Best for Heart Protection in Type 2 Diabetes?
SGLT2 inhibitors and GLP-1 agonists appear to be equally effective at protecting against stroke and myocardial infarction in patients with type 2 diabetes, but SGLT2 inhibitors are better for heart failure.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - September 28, 2021 Category: Neurology Tags: Diabetes & Endocrinology News Source Type: news

Dapagliflozin Improves Physical Limitation in HFpEF: PRESERVED-HF Dapagliflozin Improves Physical Limitation in HFpEF: PRESERVED-HF
The SGLT2 inhibitor scored a clear win, showing a significant and clinically meaningful benefit after 12 weeks for the primary endpoint, a measure of symptoms and physical limitations.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - September 14, 2021 Category: Cardiology Tags: Cardiology News Source Type: news

SGLT2 Inhibitor Use Rising in Diabetic Kidney Disease SGLT2 Inhibitor Use Rising in Diabetic Kidney Disease
' SGLT2 inhibitors are here to stay as a new standard of care for patients with diabetic kidney disease, ' said Dr Katherine Tuttle, a nephrologist at Providence Healthcare in Spokane, Washington.Medscape Medical News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - August 24, 2021 Category: Internal Medicine Tags: Diabetes & Endocrinology News Source Type: news

Aug 13 2021 This Week in Cardiology Aug 13 2021 This Week in Cardiology
COVID-19, vaccine-induced myocarditis, Watchman complications, SGLT2 inhibitors, and cardiogenic shock are the topics John Mandrola, MD, discusses in this week ’s podcast.theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - August 14, 2021 Category: Cardiology Tags: Cardiology Commentary Source Type: news

Dapagliflozin Safe, Protective in Advanced Kidney Disease Dapagliflozin Safe, Protective in Advanced Kidney Disease
' For clinicians, this is now the absolute reassurance that we do not have to stop an SGLT2 inhibitor ' in patients with advanced kidney disease, said Dr Chantal Mathieu, about the DAPA-CKD trial.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 23, 2021 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news